Clinical trials: Epstein-Barr Virus
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies.
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
- Trial name
- ADAPT-HEM (NCT07523555)
- Testing
- Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Beijing Biotech
B-cell Lymphoma, Non Hodgkin Lymphoma
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.
- Conditions
- B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT05653271
- Testing
- Cyclophosphamide, Fludarabine, ACE1831
- Where
- 13 sites in United States, Hong Kong and 1 more
- Volunteers
- 16 people
- Sponsor
- Acepodia Biotech, Inc.
Lymphoma, Acute Lymphocytic Leukemia
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
This is an open-label, dose-escalation Phase 1 study of the investigational agent, ON 013105. In laboratory animal studies, ON 013105 has demonstrated anti-cancer activity.
- Trial name
- NCT01049113
- Testing
- ON 013105
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Traws Pharma, Inc.
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
This is a open-label to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia.
- Trial name
- NCT05480501
- Testing
- IM19 CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Establishing real-world data of Chinese patients with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) treated with Puzolcabtagene Autoleucel Injection to evaluate its effectiveness.
- Trial name
- NCT07637929
- Testing
- Puzolcabtagene Autoleucel Injection
- Volunteers
- 200 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Burkitt Lymphoma, Lymphoma, Follicular
A Safety Study of SGN-CD19A for B-Cell Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
- Conditions
- Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
- Trial name
- NCT01786135
- Testing
- SGN-CD19A
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seagen Inc.
B-cell Acute Lymphoblastic Leukemia
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride
- Trial name
- NCT00289562
- Testing
- forodesine hydrochloride (BCX-1777)
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- BioCryst Pharmaceuticals
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma…
- Conditions
- Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT01397825
- Testing
- Alisertib (MLN8237), Rituximab, Vincristine
- Where
- 25 sites in United States, Italy and 2 more
- Volunteers
- 45 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.
- Conditions
- B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT07239323
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00005959
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 27 sites in United States
- Sponsor
- Amgen
Lymphoma
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
RATIONALE: Drugs used in chemotherapy, such as SL-11047, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293488
- Testing
- polyamine analogue PG11047
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Progen Pharmaceuticals
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus…
- Trial name
- NCT03397706
- Testing
- VRx-3996 and valganciclovir
- Where
- 28 sites in United States, Brazil
- Volunteers
- 64 people
- Sponsor
- Viracta Therapeutics, Inc.
Secondary Immune Deficiency
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor…
- Trial name
- NCT07648264
- Testing
- IgPro20
- Where
- 60 sites in United States, Belgium and 9 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Non-Hodgkin Lymphoma
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and…
- Trial name
- BIANCA (NCT03610724)
- Testing
- Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
- Where
- 26 sites in United States, Australia and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05309213
- Testing
- IM19 CAR-T cells
- Volunteers
- 58 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
EBV Infection
Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may cause different diseases. In most cases, EBV infection is asymptomatic because of a highly effective host immune response.
- Trial name
- EBVAST (NCT04308278)
- Testing
- 2LEBV® / 2LXFS®
- Where
- 8 sites in Belgium
- Volunteers
- 88 people
- Sponsor
- Labo'Life
Herpes Simplex
A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children
Limited data are available on valaciclovir use in children and valaciclovir is not currently approved for use in pediatrics. The marketed formulation of valaciclovir is not ideal for use in pre-adolescent patients who may have…
- Trial name
- NCT00297206
- Testing
- Valaciclovir
- Where
- 13 sites in United States, Chile and 1 more
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Burkitt Lymphoma, Precursor B-cell Lymphoblastic Leukemia-Lymphoma
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL)…
- Trial name
- NCT01786096
- Testing
- SGN-CD19A
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Seagen Inc.
B-cell Malignancy, Non-Hodgkin Lymphoma
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
- Conditions
- B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL
- Trial name
- NCT04035434
- Testing
- CTX110
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 93 people
- Sponsor
- CRISPR Therapeutics AG